国际标准期刊号: 2167-065X

临床药理学与生物药剂学

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • CAS 来源索引 (CASSI)
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • Genamics 期刊搜索
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Use of Antimalarial Drugs in Covid-19

Sarah Khan

During the recent pandemic of SARS-Covid-2 has made the clinicians to use other drugs that are known to be effective for other medical conditions. Among these repurposed therapeutic agents are the antimalarial drug chloroquine and its analogue hydroxy chloroquine, which is used for the treatment of autoimmune diseases such as SLE (systemic lupus erythematosus) and rhumatoid arthritis. These drugs have been noted having some antiviral properties in laboratory conditions. So, long story short these drugs along with a macrolide (azithromycin) were used extensively in the symptomatic treatment regimn of covid-19.
But the results came out however are a reminder of the risks of deciding to use medicines without clear evidence of their benefits and risks.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。